Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis

13th August 2018 Uncategorised 0

The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

More: Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis
Source: News